Position of the Transparency Council – Mibrex (rivaroxabanum)
At its meeting on 28 April 2025, the Transparency Council adopted position No. 49/2025 on the evaluation of the medicinal product Mibrex (rivaroxabanum) for the indication: prevention of thrombotic events in adult patients with atherosclerotic disease.